[1] National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low dose computed tomographic screening[J]. N Engl J Med, 2011, 2011(365): 395-409.
[2] The National Lung Screening Trial: Overview and Study Design. Radiology. 2010.
[3] Ettinger DS，Akerley W，Borghaei H，et a1．Non-small cell lung cancer，version 2．2013[J]．J Natl Compr Cane Netw，2013，11(6)：645-653．
[4] National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. New England Journal of Medicine, 2011, 365(5): 395-409.
[5] Kovalchik S A, Tammemagi M, Berg C D, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death[J]. New England Journal of Medicine, 2013, 369(3): 245-254
[6] Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470–8.
[7] Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst.2007;99(9):715–26
[8] Cassidy A, Myles JP, van TongerenM, Page RD, Liloglou T, DuffySW, et al. The LLP risk model: an individual risk prediction modelfor lung cancer. Br J Cancer. 2008;98(2):270–6.
[9] Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36.
[10] Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315(21):2300–11.
[11] Cronin KA, Gail MH, Zou Z, Bach PB, Virtamo J, Albanes D.Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst. 2006;98(9):637–40.
[12] Weber M, Yap S, Goldsbury D, Manners D, Tammemagi M,Marshall H, et al.Identifying high risk individuals for targeted lung cancer screening: independent validation of the PLCOM2012 risk prediction tool. Int J Cancer. 2017;
[13] D’Amelio AM Jr, Cassidy A, Asomaning K, Raji OY, Duffy SW,Field JK, et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer. 2010;103(3):423–9.
[14] Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups[J].J Thorac Cardiovasc Surg, 2012, 144 （1） :33-38
[15] Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement[J].Ann Intern Med, 2014, 160 （5） :330-338.
[16] Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE,Naidich DP, et al. Evaluation of individuals with pulmonary nodules:when is it lung cancer? Diagnosis and management of lungcancer, 3rd ed: American College of Chest Physicians evidencebasedclinical practice guidelines. Chest. 2013;143(5 Suppl):e93S–e120S.
[17] Swensen S J, Silverstein M D, Edell E S, et al. Solitary pulmonary nodules: clinical prediction model versus physicians[C]//Mayo Clinic Proceedings. Elsevier, 1999, 74(4): 319-329.
[18] Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest.
2007;131(2):383–8.
[19] Li Y, Chen K Z, Wang J. Development and validation of a clinical prediction model to estimate the probability of malignancy in solitary pulmonary nodules in Chinese people[J]. Clinical lung cancer, 2011, 12(5): 313-319.
[20] Zhang M, Zhuo N, Guo Z, Zhang X, Liang W, Zhao S, et al.Establishment of a mathematic model for predicting malignancyin solitary pulmonary nodules. J Thorac Dis. 2015;7(10):1833–41.
[21] Yang DW, Zhang XJ, Powell CA, et al. Probability of Cancer in High-Risk Patients Predicted by the Protein-Based Lung Cancer Biomarker Panel in China: LCBP Study. Cancer, 2018, 124(2):262-270.
[22] Schultz EM, Sanders GD, Trotter PR, Patz EF Jr, Silvestri GA, Owens DK, et al. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules.Thorax. 2008;63(4):335–41.
[23] Talwar A, Rahman NM, Kadir T, Pickup LC, Gleeson F. A retrospective validation study of three models to estimate the probability of malignancy in patients with small pulmonary nodules from a tertiary oncology follow-up centre. Clin Radiol. 2017;72(2): 177.e1–8.
[25] Feng F, Qiang F, Shen A, et al. Dynamic contrast-enhanced MRI versus 18F-FDG PET/CT: Which is better in differentiation between malignant and benign solitary pulmonary nodules?[J]. Chinese Journal of Cancer Research, 2018, 30(1): 21.
[26] J Thorac Dis 2018;10(Suppl 7):S797-S806
联系客服
